Decoy Therapeutics Inc. Common Stock
$2.83
-$0.06 (-2.08%)
$2.76Day Range$2.99
Key Statistics
Market Cap
$1.85M
Shares Outstanding
0.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 29, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$2.94
Day High
$2.99
Day Low
$2.76
Volume
21.6K
VWAP
$2.84
Prev Close
$2.89
Transactions
--
Acc. Volume
--
About Decoy Therapeutics Inc. Common Stock
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
PHARMACEUTICAL PREPARATIONSSIC 283411 employees2450 HOLCOMBE BLVD, HOUSTON, TX, 77021346-772-0346IPO Jan 29, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001615219
- Composite FIGI
- BBG00740LLD5
- Share Class FIGI
- BBG00740LLF3
- Ticker Root
- DCOY
- SIC Code
- 2834
About Decoy Therapeutics Inc. Common Stock (DCOY) Stock
Decoy Therapeutics Inc. Common Stock (DCOY) closed the 2026-09-17 session at $2.83, down 2.08% versus the previous close (-0.06). The stock opened at $2.94 and traded between $2.76 and $2.99 during that session. Session trading volume was 22K shares. The volume-weighted average price (VWAP) is $2.84.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
Decoy Therapeutics Inc. Common Stock has a market capitalization of $1.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. DCOY is listed on the XNAS exchange. The company employs approximately 11 people. Decoy Therapeutics Inc. Common Stock is headquartered in HOUSTON, TX. The recorded listing date is 2015-01-29.
On this page you can find market DCOY stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.